resiquimod has been researched along with Colorectal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, S; Liu, Z; Mao, H; Qiu, C; Wang, X; Xie, Y; Xiong, Y; Yu, M; Zhu, Z | 1 |
| Chen, T; Lin, G; Lin, X; Wang, X; Zhang, J | 1 |
2 other study(ies) available for resiquimod and Colorectal Neoplasms
| Article | Year |
|---|---|
TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Communication; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Imidazoles; Macrophages; Male; Membrane Glycoproteins; Mice; Myeloid-Derived Suppressor Cells; Oxaliplatin; RAW 264.7 Cells; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Microenvironment | 2020 |
Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Cytokines; Dendritic Cells; Imidazoles; Loratadine; Membrane Glycoproteins; Mice, Inbred BALB C; T-Lymphocytes, Cytotoxic; Thioridazine; Toll-Like Receptor 7 | 2020 |